Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Risk factors for chronic lymphocytic leukemia (CLL) include having a family history of CLL, being over the age of 50, exposure to certain chemicals, your biological sex, and your race. Chronic ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

Galapagos (GLPG) stock dips as Morgan Stanley downgrades its rating to Underweight from Equal Weight amid its CAR-T therapy ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Quality-of ...

Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

A Cownose stingray at the Flordia Aquarium is being recognized as a part of the nationwide World Cancer Day celebration on ...